Clinical Trials Directory

Trials / Completed

CompletedNCT05700695

Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)

Intravenous Branched-chain Amino Acids for Overt Hepatic Encephalopathy in Patients With Acute on Chronic Liver Failure - A Multi-centric Double-blind Randomized Controlled Trial

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
114 (actual)
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This multi-centric study analyses the effect of intravenous branched-chain amino acids (BCAA) on overt HE in patients with ACLF. The investigators aim to study the efficacy of combining intravenous BCAA with lactulose versus lactulose alone, ammonia measures, endotoxin, metabolomics, and cerebral edema in the medical management of overt HE in patients with ACLF. The study will also access the impact on overall survival and improvement in the grade of HE.

Detailed description

Treatment of HE in ACLF is based on extrapolation of data available from cirrhotic patients with HE. The mainstay of treatment remains Lactulose. Rifaximin is added on to therapy who have a breakthrough episode of HE on lactulose. BCAA is used as an add-on therapy if patients have minimal/covert encephalopathy, are protein intolerant or have recurrent HE. No studies are available assessing the adjuvant effect of intravenous BCAA on ammonia reduction in HE in patients with ACLF. So, this study has been designed to analyze the effect of intravenous BCAA on hepatic encephalopathy in patients with ACLF. This study will also analyze the systemic and neuronal inflammation, metabolomics, and cerebral edema under the effect of intravenous BCAA in HE patients with ACLF.

Conditions

Interventions

TypeNameDescription
DRUGBranch Chain Amino AcidIntravenous branched chain amino acids will be given for 3 days to patients in experimental arm
DRUGLactuloseOral lactulose will be given to patients in both arms

Timeline

Start date
2023-01-17
Primary completion
2025-06-05
Completion
2025-06-05
First posted
2023-01-26
Last updated
2025-06-08

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT05700695. Inclusion in this directory is not an endorsement.